Menin inhibitors are a hot topic in the field of acute myeloid leukemia (AML), with the potential to provide a novel treatment option for patients with this malignancy. Harry Erba, MD, PhD, Duke University, Durham, NC, briefly outlines the mechanism of action of menin inhibitors before discussing some of the current data on menin inhibition in AML. Dr Erba provides insight into a study investigating DSP-5336 (NCT04988555), as well as mentioning the BEAT AML trial (NCT03013998), which combines revumenib with azacitidine and venetoclax in newly diagnosed older patients. There is also growing interest in identifying an expression signature that may predict the efficacy of menin inhibitors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть